Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With Cirrhosis
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This investigational trial will be assessing the effect of rifaximin on pathophysiology and
haemodynamics in the patient with liver cirrhosis, and addressing the effect of rifaximin on
several organs on marker level. The molecular and physiological effects of rifaximin will be
explored.
The investigators hypothesize that intestinal decontamination with rifaximin in patients with
cirrhosis and ascites will interrupt bacterial translocation from the gut, diminish the
following inflammatory response, prevent splanchnic vasodilatation and portal systemic
contraction and thereby reduce the risk clinical complications to cirrhosis.
If rifaximin can correct small intestinal bacterial overgrowth and demonstrate improvement in
liver haemodynamics, renal function and systemic dynamics, then these effects may contribute
to the overall well-being of the patient and prevent complications to the underlying
cirrhosis such as risk of infections, progression of disease, and admission to hospital.
Phase:
Phase 4
Details
Lead Sponsor:
Copenhagen University Hospital, Hvidovre
Collaborators:
Norgine Region MidtJylland Denmark Statens Serum Institut